Secondary amyloidosis laboratory findings

Revision as of 19:34, 7 November 2019 by Sahar Memar Montazerin (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Secondary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Secondary amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Secondary amyloidosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Secondary amyloidosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Secondary amyloidosis laboratory findings

CDC on Secondary amyloidosis laboratory findings

Secondary amyloidosis laboratory findings in the news

Blogs on Secondary amyloidosis laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Secondary amyloidosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Shaghayegh Habibi, M.D.[3]

Overview

An elevated urinary protein is suggestive of secondary amyloidosis. Elevated level of acute phase reactant, abnormal liver function test, and other findings may also be observed.

Laboratory Findings

  • Laboratory findings suggestive of secondary amyloidosis vary depending on the affected organ.[1]
  • The most commonly observable finding is proteinuria, particularly nephrotic range (>3.5 g/day).
  • Other possible laboratory findings include:[2]

References

  1. Papa, Riccardo; Lachmann, Helen J. (2018). "Secondary, AA, Amyloidosis". Rheumatic Disease Clinics of North America. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. ISSN 0889-857X.
  2. Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.

Template:WH Template:WS